--- title: "BiomX Delays Quarterly Report Amid Strategic Shift" type: "News" locale: "en" url: "https://longbridge.com/en/news/286624580.md" description: "BiomX has announced a delay in filing its Quarterly Report for the period ended March 31, 2026, due to the need for additional time to compile information on significant transactions. The company is undergoing a strategic shift, including a new board and expansion into defense technology. BiomX reported $3.0 million from Series Y financing and $3.3 million from warrant exercises. The results for the quarter are expected to differ materially from the previous year due to operational changes and insolvency proceedings." datetime: "2026-05-15T23:38:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286624580.md) - [en](https://longbridge.com/en/news/286624580.md) - [zh-HK](https://longbridge.com/zh-HK/news/286624580.md) --- # BiomX Delays Quarterly Report Amid Strategic Shift BiomX ( (PHGE) ) has released a notification of late filing. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks BiomX Inc. has filed a Form 12b-25, notifying investors that it will delay its Quarterly Report on Form 10-Q (Quarter Report) for the period ended March 31, 2026. The company says the delay stems from the time needed to obtain and compile information on significant transactions completed during the quarter. These transactions are material enough that management concluded they could not meet the deadline without unreasonable effort and expense. BiomX confirms it has been current with all other required SEC periodic filings over the past 12 months. The company expects to file the delayed Form 10-Q (Quarter Report) within the standard SEC grace period, specifically no later than the fifth calendar day after the original due date. Investors should therefore anticipate the 10-Q (Quarter Report) becoming available shortly after this notification date. BiomX warns that its results for the quarter ended March 31, 2026 will differ materially from the same quarter in 2025. The changes are linked to the shutdown of its Phase 2b clinical trial of BX004, a sharp reduction in research and development activities, and the start of insolvency proceedings for its pre-restructuring Israeli operating subsidiary, which has been deconsolidated. The company has also undergone a major strategic and governance shift, including a reconstituted board and executive team and an expansion into defense, security and critical infrastructure technology markets. On the financing side, BiomX reports $3.0 million of gross proceeds from a Series Y financing in January 2026 and $3.3 million from warrant exercises in March, with all Series Y preferred shares converted into common stock. Because the financial close process and the detailed accounting for the Series Y financing are still in progress, BiomX is not yet providing quantitative estimates of the quarter’s results. The statements about expected changes in operations and the timing of the filing are forward-looking and depend on completion of the closing process and final accounting judgments. The company states it is working to complete its financial reporting and maintain compliance with SEC requirements. The notification was signed on May 15, 2026 by Chief Executive Officer Michael Oster, underscoring executive-level oversight of the delayed Form 10-Q (Quarter Report). The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page. **Spark’s Take on PHGE Stock** According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral. The score is driven primarily by weak financial performance (no revenue history, ongoing cash burn, and negative equity) and strongly bearish technicals (price far below key moving averages with negative MACD and very low RSI/Stochastic). Corporate events add both upside (defense-tech pivot and new contracts) and significant risk (insolvency-linked restructuring, delisting noncompliance, and dilution/integration concerns), while valuation is limited by a negative P/E and no dividend support. To see Spark’s full report on PHGE stock, click here. **More about BiomX** **Average Trading Volume:** 217,427 **Technical Sentiment Signal:** Sell **Current Market Cap:** $5.91M ### Related Stocks - [PHGE.US](https://longbridge.com/en/quote/PHGE.US.md) ## Related News & Research - [BiomX Acquires DFSL To Expand Defense Portfolio](https://longbridge.com/en/news/282652127.md) - [Teledyne FLIR Defense Announces New ‘Block 2’ Upgrades to Rogue 1 Lethal Unmanned Aerial System | TDY Stock News](https://longbridge.com/en/news/287049869.md) - [Mach Industries just spent $50M to solve a major defense tech problem](https://longbridge.com/en/news/286967765.md) - [Vuzix Showcasing Advanced Waveguide Solutions for Defense and Tactical Operations During SOF Week 2026 | VUZI Stock News](https://longbridge.com/en/news/286950584.md) - [ZenaTech Advances Three ZenaDrone Defense Platforms Through Blue UAS Certification Pathway | ZENA Stock News](https://longbridge.com/en/news/286910480.md)